News
-
Immunovative Announces Regulatory Clearance To Conduct A Phase II/III Clinical Trial In Advanced Metastatic Breast Cancer For AlloStim™
11/29/2012
Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) announces today that Immunovative Therapies, Ltd. ("ITL") has been granted regulatory clearance from Thailand authorities to advance its lead AlloStim™ immunotherapy product candidate to the Phase II/III clinical development stage in advanced metastatic breast cancer.
-
Kinexum And Pennington Biomedical Announce Collaboration For Accelerating Clinical Research Innovation
9/24/2012
Kinexum and Pennington Biomedical Research Center announced plans to establish an integrated approach for emerging companies and early stage therapies to achieve high value regulatory and early phase human clinical trials.
-
Xcovery Announces Presentation Of Clinical Data At Upcoming ASCO Annual Meeting
5/18/2012
Xcovery, a developer of next-generation targeted therapeutics for cancer, today announced that investigators will present data from its Phase 1 clinical study which evaluated X-82, an oral VEGFR tyrosine kinase inhibitor (TKI), in patients with advanced solid tumors.
-
iCardiac Technologies’ Growth Accelerates Revenue Growth Exceeds 140% Supported By Expansion Of Operations
4/22/2012
iCardiac Technologies, Inc., a provider of next generation cardiac core lab services, announced recently it has recorded another increase in its growth rate.
-
Quotient Announces Agreement With Phico Therapeutics And First Application Of RapidFACT For Nasal Delivery
9/14/2011
Quotient Clinical, a business unit of Quotient Bioresearch (Quotient), recently announced an agreement with UK-based biotech, Phico Therapeutics (Phico).
-
Quotient Announces The First Use Of ivMicrotracer To Support A Regulatory Drug Approval Submission
9/7/2011
Quotient Clinical, a business unit of Quotient Bioresearch (Quotient), recently announced that absolute bioavailability data from an ivMicrotracer study has been used to support a submission for regulatory drug approval.
-
Spaulding Clinical Announces Strategic Partnership With Clinigene International, India For Providing Comprehensive Early Clinical Solutions To Pharmaceutical And Biotech Clients
8/23/2011
Clinigene International Limited, an India-based Central and Bioanalytical Laboratory and Phase I-IV Clinical Research Organization, and Spaulding Clinical Research, LLC, US-based leading-edge Clinical Pharmacology, Cardiac Core Lab, and Medical Device Manufacturer, announce a strategic partnership agreement.
-
Spaulding Clinical Announces New Joint Partnership For Global Studies With Eurofins Optimed Clinical Research
8/9/2011
Eurofins Optimed Clinical Research, an experienced European clinical research service provider and Spaulding Clinical Research, LLC., US-based, leading-edge Clinical Pharmacology, Cardiac Core Lab, and Medical Device Manufacturer, announce a joint partnership agreement.
-
PAREXEL Achieves 100th Asian Ethnobridging Study Milestone
7/25/2011
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.
-
inVentiv Health Completes PharmaNet Acquisition
7/15/2011
inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced it has completed the acquisition of PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries.